Season’s Greetings: A Word from the CEO
2016 has been a standout year for Xeltis. We have realized some significant milestones, which we’re exceptionally proud of.
Xeltis completed enrollment in the Xplore-I feasibility clinical study for our pulmonary valve; data on our technology has been presented at six globally recognized scientific and medical meetings; we have expanded our RestoreX technology platform, with aortic valve and other applications in preclinical phase; finally, 18 world-class experts joined our Clinical and Scientific Advisory Boards.
To all our viewers and followers, thank you for your ongoing interest and support for Xeltis, for our technology and for the future of cardiovascular treatment. We look forward to more leaps in 2017.